Correlation Between Testosterone and PSA Kinetics in Metastatic Prostate Cancer Patients Treated With Diverse Chemical Castrations
|
|
- Florence King
- 6 years ago
- Views:
Transcription
1 552468JMHXXX / American Journal of Men s HealthReis et al. research-article2014 Article Correlation Between Testosterone and PSA Kinetics in Metastatic Prostate Cancer Patients Treated With Diverse Chemical Castrations American Journal of Men s Health 2015, Vol. 9(5) The Author(s) 2014 Reprints and permissions: sagepub.com/journalspermissions.nav DOI: / ajmh.sagepub.com Leonardo O. Reis, MD, MSc, PhD 1,2, Fernandes Denardi, MD, PhD 2, Eliney F. Faria, MD, PhD 3, and Elcio Dias Silva, MD, PhD 4 Abstract To assess total testosterone and prostatic-specific antigen (PSA) kinetics among diverse chemical castrations, advanced-stage prostate cancer patients were randomized into three groups of 20: Group 1, Leuprolide 3.75 mg; Group 2, Leuprolide 7.5 mg; and Group 3, Goserelin 3.6 mg. All groups were treated with monthly application of the respective drugs. The patients levels of serum total testosterone and PSA were evaluated at two time periods: before the treatment and 3 months after the treatment. Spearman s rank correlation coefficient was utilized to verify the hypothesis of linear correlation between total testosterone and PSA levels. At the beginning the patients age, stage, grade, PSA, and total testosterone were similar within the three groups, with median age 72, 70, and 70 years in Groups 1, 2, and 3, respectively. Three months after the treatment, patients who received Leuprolide 7.5 mg presented significantly lower median total testosterone levels compared with Goserelin 3.6 mg and Leuprolide 3.75 mg (9.5 ng/dl vs ng/dl vs ng/dl, respectively; p =.0072), while those who received Goserelin 3.6 mg presented significantly lower PSA levels compared with Leuprolide 7.5 mg and Leuprolide 3.75 mg (0.67 vs vs. 2.57, respectively; p =.0067). There was no linear correlation between total testosterone and PSA levels. Overall, regarding castration levels of total testosterone, 28.77% of patients did not obtain levels 50 ng/dl and 47.80% did not obtain levels 20 ng/dl. There was no correlation between total testosterone and PSA kinetics and no equivalence among different pharmacological castrations. Keywords bioavailable testosterone, luteinizing hormone-releasing hormone, LHRH agonists, prostatic specific antigen, pharmacological castration and surgical castration Introduction Androgen suppression is an effective treatment for prostate cancer in advanced stages, controlling the disease in 80% to 90% of men with results in progression-free survival of approximately 12 to 33 months (Denis & Murphy, 1993). The use of luteinizing hormone-releasing hormone (LHRH) agonists and antiandrogenics began in the 1980s and today represents a standard alternative to surgical castration for patients with prostate cancer and metastases. The LHRH agonists, such as Goserelin and Leuprolide, have been reported to be as effective as surgical castration (Hellerstedt & Pienta, 2002; Seidenfeld et al., 2000). However, some studies have identified that the grade of potency of LHRH analog peptides varies according to their modified amino acid structures, and thus the effect on the pituitary gonadal axis may vary with the agent. Several studies suggested that serum testosterone is not always suppressed below the upper limit of the castration range in patients using LHRH agonists, especially Leuprolide acetate (Heyns, Simonin, Grosgurin, Schall, & Porchet, 2003; Oefelein & Cornum, 2000; Smith & McGovern, 2001; Yri, Bjoro, & Fossa, 2006). 1 Pontifical Catholic University of Campinas, Campinas, Brazil 2 University of Campinas Unicamp, Campinas, Brazil 3 Barretos Cancer Hospital, Barretos, Brazil 4 Maternidade de Campinas e Hospital Sírio Libanês, São Paulo, Brazil Corresponding Author: Leonardo O. Reis, Urology Division, Faculty of Medicine, Pontifical Catholic University of Campinas, PUC-Campinas, Av. John Boyd Dunlop s/n, CEP , Campinas, São Paulo, Brazil. reisleo.l@gmail.com
2 Reis et al. 431 Studies correlating testosterone and prostatic-specific antigen (PSA) kinetics among diverse chemical castrations are lacking and total testosterone may not represent the real exposure to bioavailable and active free testosterone. This study assessed the equivalence of Leuprolide 3.75 mg, Leuprolide 7.5 mg, and Goserelin 3.6 mg in terms of correlation between serum total testosterone (TT) and PSA variations. Method Prospectively, this study included 60 patients with advanced prostate carcinoma, with indication for hormone blockade. The patients were randomized into three groups of 20 based on the order of arrival and urologic oncology reference center: Group 1 received Leuprolide 3.75 mg, Group 2 received Leuprolide 7.5 mg, and Group 3 received Goserelin 3.6 mg. All groups were treated with monthly application of the respective drugs. Group 1 had one patient excluded because of a testosterone level of castration before randomization. The subjects were selected from two reference urologic oncology centers. The patients from the first center received Leuprolide 3.75 mg or Goserelin 3.6 mg, and the patients from the second center received Leuprolide 7.5 mg. After written consent, the selected patients were submitted to total testosterone and PSA tests and initiated the treatment with one of the three drugs. Patients who had previously undergone hormone blockade treatments and patients who already presented castration testosterone levels were not included in the study. The drugs were administered once a month during 3 months. After the conclusion of the proposed treatment, the patients were followed in the respective services, with the drugs that were appointed to the respective groups and under the same rules of procedure for patients with advanced prostate cancer. The patients levels of serum total testosterone and PSA were evaluated at two time periods: before the treatment and 3 months after the treatment. The testosterone concentration was taken with microparticle enzyme immunoassay (MEIA) in the patients of Groups 1 and 3 and with eletrochemiluminescence-testosterone II (cobas) Elecys and cobas analyzers (Roche Diagnostics GmbH) in Group 2. The proportion of chemically castrated patients for cutoffs, defined as 50 ng/dl and 20 ng/dl of testosterone, was compared in the three groups. Statistics Kruskal Wallis test compared pretreatment variables. Spearman s rank correlation coefficient was utilized to verify the hypothesis of linear correlation between total testosterone and PSA levels. Spearman s coefficient varies from 1 (negative correlation) to 1 (positive correlation). Values close to zero denote no correlation. ANOVA test compared the three groups in the follow-up, and Tukey test confirmed differences between groups. Significance level was considered 5% (p <.05). Results At the beginning of study, the patients age, disease stage, grade and volume (presence of visceral metastases), total testosterone, and PSA were not significantly different within the three groups (p >.05). Range, median, and average age for group 1 were 58-88, 72, and 71.4 years for Group 1; 56-81, 70, and 69.6 years for Group 2; and 58-86, 70, and 71.3 years for Group 3, respectively. Three months after the treatment, there was no linear correlation between total testosterone and PSA levels, overall (n = 59) and in each group (see Figure 1). Spearman s coefficient (p value): Goserelin 3.6 mg = (.6934), Leuprolide 3.75 mg = (.6524), Leuprolide 7.5 mg = (.4031), overall = (.6757). Patients who received Leuprolide 7.5 mg presented significantly lower median total testosterone levels compared with Goserelin 3.6 mg and Leuprolide 3.75 mg (9.5 ng/dl vs ng/dl vs ng/dl, respectively; p =.0072), while those who received Goserelin 3.6 mg presented significantly lower PSA levels compared with Leuprolide 7.5 mg and Leuprolide 3.75 mg (0.67 vs vs. 2.57, respectively; p =.0067; see Figure 2). Regarding castration levels of total testosterone, 28.77% of patients did not obtain levels 50 ng/dl (26.3%, 25%, and 35% of patients in Leuprolide 3.75 mg, Leuprolide 7.5 mg, and Goserelin 3.6 mg groups, respectively; p =.751 for the difference of proportions). Furthermore, 47.8% of patients did not obtain levels 20 ng/dl (68.4%, 30%, and 45% of patients in Leuprolide 3.75 mg, Leuprolide 7.5 mg, and Goserelin 3.6 mg groups, respectively; p =.054). There were no differences in terms of tumor grade, stage, and volume of disease (presence of visceral metastases) when comparing those that reached or did not reach castration levels. Discussion This preliminary study dissects the connection between testosterone and PSA kinetics in metastatic prostate cancer patients treated with diverse chemical castrations and for the first time identifies no linear correlation between total testosterone and PSA variations, supporting the hypothesis that efficacy in terms of TT and PSA variations independently varies among LHRH analogs. Though PSA is routinely measured to provide an indication of disease control, results from a meta-analysis,
3 432 American Journal of Men s Health 9(5) Figure 1. Spearman s rank correlation coefficient (p value) between total testosterone and PSA. Figure 2. Median PSA and testosterone variations among groups. utilizing data from three randomized clinical trials, suggested that PSA could not be statistically validated as a surrogate for overall survival. However, patients in such study were not treated uniformly and PSA was not monitored in a similar way (Collette et al., 2005). Sustaining the controversy, subsequent studies reported that effective PSA control (Hussain et al., 2009) and a shorter PSA half-life (faster PSA reduction) are associated with improved prostate cancer progression and overall survival (Hanninen, Venner, & North, 2009; Lin et al., 2009). The main purpose of any type of hormonal blockade is to reach testosterone levels less than 50 ng/dl, which is, historically, considered castration level (Oefelein & Cornum, 2000; Perez-Marreno et al., 2002). Nevertheless, there are controversies regarding this level, because it derives from the older measurement method used in the 1960s and 1970s, which was known as isotope derivative dilution technique, that considered 50 ng/dl as the lower limit for detection (Novara, Galfano, Secco, Ficarra, & Artibani, 2009; Tombal, 2005). In this context, the equivalence of surgical and different pharmacological castrations has been contested (Dias Silva et al., 2012). Besides that, there is a cluster of evidence supporting the hypothesis that the lower the better when achieving castration levels of testosterone, based on the data from second-line hormonal manipulation and its molecular basis (Reis, 2011, 2012), and on better oncological results reported for patients with castration levels <32 ng/dl (Morote et al., 2007). There is rapidly growing evidence that the depth of the testosterone nadir is associated with a survival advantage in men with metastatic prostate cancer (Perachino, Cavalli, & Bravi, 2010), yet without PSA/testosterone correlation analysis, the original scope of the present study. In terms of PSA variations among different LHRH analogs, recent data suggest that about 70% of patients experienced decreased PSA after the LHRH switch, and this decrease appeared more pronounced when switching from Leuprolide to Goserelin rather than vice versa (Lawrentschuk, Fernandes, Bell, Barkin, & Fleshner, 2001). These data suggest that the pharmacodynamics of these agents may be different and are in line with our results that confirm that the lowest levels of PSA occurred in patients under Goserelin 3.6 mg, even though starting from not significantly different levels. Another interesting fact is that Goserelin is the only LHRH agonist that has been described to improve overall survival when used as an adjuvant to radiotherapy in locally advanced disease (Bolla et al., 2002; Pilepich et al., 2005) and to radical prostatectomy in patients with nodepositive disease (Messing et al., 1999). This may be related to lowest PSA levels and might occur independent of total testosterone variations, once the lowest TT levels occurred in patients under Leuprolide 7.5 mg treatment when comparing LHRH analogs. There are few studies directly comparing the different LHRH analogs, and most include a small number of patients, are not randomized and limited to TT levels, and are lacking PSA and survival analysis (Fujii et al., 2008; Kuhn et al., 1997; Smith, 2007; Tanaka et al., 2007). Adding to the LHRH disparities, there appears to be a correlation between a greater body mass index (BMI) and greater concentrations of free testosterone in patients under chemical castration (Smith, 2007; van der
4 Reis et al. 433 Sluis et al., 2013). A potential relationship between BMI and the development and/or progression of prostate cancer might be caused by elevated free testosterone levels and by a potential difference in pharmacodynamics among normal weight, overweight, and obese patients receiving LHRH agonist therapy for prostate cancer (van der Sluis et al., 2013). One robust hypothesis explaining no correlation between TT and PSA kinetics is that free (bioavailable) testosterone may be the main factor driving PSA and disease control, but not total testosterone, and different medicines may present different efficiency in lowering the bioavailable testosterone. In fact, the role of free testosterone in prostate cancer remains unclear, supporting the bioavailable testosterone hypothesis. The best marker of hormonal deprivation efficacy is to be defined, and free (bioavailable) testosterone concentrations could be an interesting topic for future research, especially with the increased possibilities of testosterone measurement in the castrate range using ultrasensitive technique of serum testosterone measurement and considering that no correlation between TT and PSA variations was achieved in the setting of diverse chemical castrations in this study. Free testosterone deserves more research regarding its relation to clinical outcomes once it may better reflect prostate cancer tissue androgen levels than serum total testosterone concentration (Rove et al., 2014). In this scenario, a recent study is in line with our results, recognizing the clinical utility of these new data. The authors report that while Leuprolide was more efficient in lowering TT, an oral selective estrogen receptor alpha agonist (GTx-758) lowered free testosterone and PSA more than Leuprolide (Yu et al., 2014). These findings add to the current study to underscore the importance of other markers over TT as a more accurate measure of available circulating testosterone, supporting the free hormone hypothesis where free testosterone levels better correlate with PSA kinetics and androgen action. It is important to highlight that while original, our study is not devoid of limitations, including a relatively small number of patients with short follow-up. Additionally, BMI and tumor neuroendocrine differentiation were not assessed and might affect PSA and TT levels. Confirmatory trials will need stronger methodology with patients stratification, analyzing disease progression and survival to add to this hypothesis generating study. Besides, LHRH antagonists should also be compared with agonists, considering different times to achieve castration level with potential different clinical outcomes between them. Conclusions This prospective randomized study complements recent data contesting the equivalence of different pharmacological castrations regarding TT and PSA levels. Also, there was no correlation between TT and PSA kinetics in the setting of chemical castration. While Goserelin 3.6 mg reported the lowest PSA levels, the lowest TT levels occurred in the Leuprolide 7.5 mg treatment, even starting from not significantly different groups in terms of TT, PSA, age, and disease stage, grade, and volume. Labeling and classifying LHRH agonists from a regulatory perspective in different classes according to their efficacy in terms of TT and PSA variations appears warranted. Declaration of Conflicting Interests The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Funding The author(s) received no financial support for the research, authorship, and/or publication of this article. References Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J. B., Mirimanoff, R. O.,... Pierart, M. (2002). Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet, 360, Collette, L., Burzykowski, T., Carroll, K. J., Newling, D., Morris, T., & Schröder, F. H. (2005). Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and Astra Zeneca Pharmaceuticals. Journal of Clinical Oncology, 23, Denis, L., & Murphy, G. P. (1993). Overview of Phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer, 72(12 Suppl.), Dias Silva, E., Ferreira, U., Matheus, W., Faria, E. F., Silva, G. D., Saito, M.,... Reis, L. O. (2012). Goserelin versus Leuprolide in the chemical castration of patients with prostate cancer. International Urology and Nephrology, 44, Fujii, Y., Yonese, J., Kawakami, S., Yamamoto, S., Okubo, Y., & Fukui, I. (2008). Equivalent and sufficient effects of Leuprolide acetate and Goserelin acetate to suppress serum testosterone levels in patients with prostate cancer. BJU International, 101, Hanninen, M., Venner, P., & North, S. (2009). A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer. Canadian Urological Association Journal, 3, Hellerstedt, B. A., & Pienta, K. J. (2002). The current state of hormonal therapy for prostate cancer. CA: A Cancer Journal for Clinicians, 52, Heyns, C. F., Simonin, M. P., Grosgurin, P., Schall, R., & Porchet, H. C. (2003). Comparative efficacy of triptorelin
5 434 American Journal of Men s Health 9(5) pamoate and Leuprolide acetate in men with advanced prostate cancer. BJU International, 92, Hussain, M., Goldman, B., Tangen, C., Higano, C. S., Petrylak, D. P., Wilding, G.,... Crawford, E. D. (2009). Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and Journal of Clinical Oncology, 27, Kuhn, J. M., Abourachid, H., Brucher, P., Doutres, J. C., Fretin, J., Jaupitre, A.,...Dufour-Esquerré, F. (1997). A randomized comparison of the clinical and hormonal effects of two GnRH agonists in patients with prostate cancer. European Urology, 32, Lawrentschuk, N., Fernandes, K., Bell, D., Barkin, J., & Fleshner, N. (2001). Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence. Journal of Urology, 185, Lin, G. W., Yao, X. D., Zhang, S. L., Dai, B., Ma, C. G., Zhang, H. L.,...Ye, D. W. (2009). Prostate-specific antigen halflife: A new predictor of progression-free survival and overall survival in Chinese prostate cancer patients. Asian Journal of Andrology, 11, Messing, E. M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E. D., & Trump, D. (1999). Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. New England Journal of Medicine, 341, Morote, J., Orsola, A., Planas, J., Trilla, E., Raventos, C. X., Cecchini, L., & Catalán, R. (2007). Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. Journal of Urology, 178(4 Pt 1), Novara, G., Galfano, A., Secco, S., Ficarra, V., & Artibani, W. (2009). Impact of surgical and medical castration on serum testosterone level in prostate cancer patients. Urologia Internationalis, 82, Oefelein, M. G., & Cornum, R. (2000). Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: The case for monitoring serum testosterone and a treatment decision algorithm. Journal of Urology, 164(3 Pt 1), Perachino, M., Cavalli, V., & Bravi, F. (2010). Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: Prognostic significance? BJU International, 105, Perez-Marreno, R., Chu, F. M., Gleason, D., Loizides, E., Wachs, B., & Tyler, R. C. (2002). A six-month, open-label study assessing a new formulation of Leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clinical Therapeutics, 24, Pilepich, M. V., Winter, K., Lawton, C. A., Krisch, R. E., Wolkov, H. B., Movsas, B.,...Grignon, D. (2005). Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: Long-term results of phase III RTOG International Journal of Radiation Oncology, Biology, and Physics, 61, Reis, L. O. (2011). Old issues and new perspectives on prostate cancer hormonal therapy: The molecular substratum. Medical Oncology, 29, Reis, L. O. (2012). Variations of serum testosterone levels in prostate cancer patients under LH-releasing hormone therapy: An open question. Endocrine Related Cancer, 19(3), R93-R98. Rove, K. O., Crawford, E. D., Perachino, M., Morote, J., Klotz, L., Lange, P. H.,...Reis, L.O. (2014). Maximal testosterone suppression in prostate cancer: Free vs total testosterone. Urology, 83, Seidenfeld, J., Samson, D. J., Hasselblad, V., Aronson, N., Albertsen, P. C., Bennett, C. L., & Wilt, T. J. (2000). Singletherapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis. Annals of Internal Medicine, 132, Smith, M. R. (2007). Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer. Clinical Cancer Research, 13, Smith, M. R., & McGovern, F. J. (2001). Gonadotropinreleasing hormone agonist failure in a man with prostate cancer. Journal of Urology, 166, 211. Tanaka, N., Fujimoto, K., Hirao, Y., Shimizu, K., Tsujimoto, S., & Samma, S. (2007). Endocrine response to a single injection of Goserelin 3.6 mg or Leuprolide 3.75 mg in men with prostate cancer. Archives of Andrology, 53(2), Tombal, B. (2005). Appropriate castration with luteinizing hormone releasing hormone (LHRH) agonists: What is the optimal level of testosterone? European Urology, 4(1), van der Sluis, T. M., van Moorselaar, R. J., Meuleman, E. J., Ter Haar, R. W., Bui, H. N., Heijboer, A. C., & Vis, A. N. (2013). Relationship between body mass index and serum testosterone concentration in patients receiving luteinizing hormone-releasing hormone agonist therapy for prostate cancer. Urology, 81, Yri, O. E., Bjoro, T., & Fossa, S. D. (2006). Failure to achieve castration levels in patients using Leuprolide acetate in locally advanced prostate cancer. European Urology, 49(1), Yu, E. Y., Getzenberg, R. H., Coss, C. C., Gittelman, M. M., Keane, T., Tutrone, R.,...Steiner, M. C. (2014). Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer. European Urology. Advance online publication. doi: /j.eururo
Goserelin versus leuprolide in the chemical castration of patients with prostate cancer
Int Urol Nephrol (2012) 44:1039 1044 DOI 10.1007/s11255-012-0134-z UROLOGY ORIGINAL PAPER Goserelin versus leuprolide in the chemical castration of patients with prostate cancer Élcio Dias Silva Ubirajara
More informationEligard W 6: A New Form of Treatment for Prostate Cancer
european urology supplements 5 (2006) 905 910 available at www.sciencedirect.com journal homepage: www.europeanurology.com Eligard W 6: A New Form of Treatment for Prostate Cancer Oliver Sartor * Dana
More informationChanges in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer
Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer S Egawa 1 *, H Okusa 1, K Matsumoto 1, K Suyama 1 & S Baba 1 1 Department
More informationDefinition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
More informationClinical significance of suboptimal hormonal levels in men with prostate cancer treated with LHRH agonists
original research research research Clinical significance of suboptimal hormonal levels in men with prostate cancer treated with LHRH agonists Jun Kawakami, MD, FRCSC; * Alvaro Morales, MD, FRCSC, OC *Department
More informationProstate cancer is now the most
: a new hormonal treatment for prostate cancer Professor Malcolm Mason, School of Medicine, Cardiff University, Velindre Hospital, Whitchurch, Cardiff - hypothalamus According to NICE, prostate cancer
More informationHormonotherapy of advanced prostate cancer
Annals of Oncology 16 (Supplement 4): iv80 iv84, 2005 doi:10.1093/annonc/mdi913 Hormonotherapy of advanced prostate cancer P. Pronzato & M. Rondini Department of Oncology, Felettino Hospital, La Spezia,
More informationMaximal androgen blockade versus castration alone in patients with metastatic prostate cancer*
Chinese-German J Clin Oncol DOI 10.1007/s10330-014-0037-9 September 2014, Vol. 13, No. 9, P417 P421 Maximal androgen blockade versus castration alone in patients with metastatic prostate cancer* Abeer
More informationlower testosterone levels with LHRH agonist therapy than with surgical castration: new insights attained by mass spectrometry
6 lower testosterone levels with LHRH agonist therapy than with surgical castration: new insights attained by mass spectrometry Hong N. Bui, Tim M. van der Sluis, Eric J.H. Meuleman, Annemieke C. Heijboer,
More informationMedical management in locally advanced and metastatic prostate cancer: Does changes in treatment policy have any specific effect on PSA levels?
ORIGINAL PAPER DOI: 10.4081/aiua.2017.4.282 Medical management in locally advanced and metastatic prostate cancer: Does changes in treatment policy have any specific effect on PSA levels? Murat Bagcioglu
More information2. The effectiveness of combined androgen blockade versus monotherapy.
Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer Blue Cross and Blue Shield Association, Aronson N, Seidenfeld J Authors' objectives
More informationWhat is New in Hormone Therapy for Prostate Cancer in 2007?
european urology supplements 7 (2008) 477 483 available at www.sciencedirect.com journal homepage: www.europeanurology.com What is New in Hormone Therapy for Prostate Cancer in 2007? Bertrand Tombal *
More informationThe use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective randomised trials
British Journal of Cancer (2004) 90, 950 954 All rights reserved 0007 0920/04 $25.00 www.bjcancer.com Minireview The use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective
More informationExpert Opinion on Optimal Testosterone Control in Prostate Cancer
European Urology Supplements European Urology Supplements 4 (2005) 37 41 Expert Opinion on Optimal Testosterone Control in Prostate Cancer Alex Zlotta a,1, Frans M.J. Debruyne b, * a Department of Urology,
More informationHow Should WeTreat Patients with Locally Advanced Prostate Cancer?
European Urology Supplements European Urology Supplements 2 (2003) 14 22 How Should WeTreat Patients with Locally Advanced Prostate Cancer? Malcolm Mason * Section of Oncology and Palliative Medicine,
More informationHormone therapy works best when combined with radiation for locally advanced prostate cancer
Hormone therapy works best when combined with radiation for locally advanced prostate cancer Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Introduction Introduction 1/3 of patients
More informationAppropriate Castration with Luteinising Hormone Releasing Hormone (LHRH) Agonists: What is the Optimal Level of Testosterone?
European Urology Supplements European Urology Supplements 4 (2005) 14 19 Appropriate Castration with Luteinising Hormone Releasing Hormone (LHRH) Agonists: What is the Optimal Level of Testosterone? B.
More informationHormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice
european urology supplements 5 (2006) 362 368 available at www.sciencedirect.com journal homepage: www.europeanurology.com Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice Antonio
More informationVol. 36, pp , 2008 T1-3N0M0 : T1-3. prostate-specific antigen PSA. 68 Gy National Institutes of Health 10
25 Vol. 36, pp. 25 32, 2008 T1-3N0M0 : 20 2 18 T1-3 N0M0 1990 2006 16 113 59.4-70 Gy 68 Gy 24 prostate-specific antigen PSA 1.2 17.2 6.5 5 91 95 5 100 93 p 0.04 T3 PSA60 ng ml 68 Gy p 0.0008 0.03 0.04
More informationEfficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer
Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer Jean De La Rosette, Ronald Davis Iii, David Frankel, Tine
More informationUpdates in Prostate Cancer Treatment 2018
Updates in Prostate Cancer Treatment 2018 Mountain States Cancer Conference Elaine T. Lam, MD November 3, 2018 Learning Objectives Understand the difference between hormone sensitive and castration resistant
More informationMetastatic prostate carcinoma. Lee Say Bob July 2017
Metastatic prostate carcinoma Lee Say Bob July 2017 Scenario A 58 year old gentleman presents with PSA 200 ng/ml with hard prostate and bone mets. LUTS but upper tracts are normal with normal RP. history
More informationmajority of the patients. And taking an aggregate of all trials, very possibly has a modest effect on improved survival.
Hello. I am Farshid Dayyani. I am Assistant Professor in Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center. We will be talking today about prostate cancer for survivorship
More informationUrologic Oncology: Seminars and Original Investigations 30 (2012) 3 15
Urologic Oncology: Seminars and Original Investigations 30 (2012) 3 15 Review article The multi-disciplinary management of high-risk prostate cancer Jonathan C. Picard, M.D. a, *, Ali-Reza Golshayan, M.D.
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationProstate Cancer in comparison to Radiotherapy alone:
Prostate Cancer in comparison to Radiotherapy alone: 1 RTOG 86-10 (2001) 456 patients with > a-goserelin 2 month before RTand during RT + Cyproterone acetate (1 month) vs b-pelvic irradiation (50 gy) +
More informationTiming of Androgen Deprivation: The Modern Debate Must be conducted in the following Contexts: 1. Clinical States Model
Timing and Type of Androgen Deprivation Charles J. Ryan MD Associate Professor of Clinical Medicine UCSF Comprehensive Cancer Center Timing of Androgen Deprivation: The Modern Debate Must be conducted
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationIntroduction. Key Words: androgen deprivation therapy, prostate cancer, castration resistant prostate cancer, androgen receptor, CRPC
Traditional androgen ablation approaches to advanced prostate cancer: new insights Kyle O. Rove, MD, E. David Crawford, MD Division of Urology, University of Colorado, Anschutz Medical Campus, Aurora,
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND
More informationNational Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:
Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A PHASE III STUDY OF IRESSA
More informationThe Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage for Metastatic Prostate Cancer
Research Article TheScientificWorldJOURNAL (005) 5, 8 4 ISSN 57-744X; DOI 0.00/tsw.005.9 The Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage
More informationHormone Therapy: Improving Therapy Decisions and Monitoring
european urology supplements 5 (2006) 369 376 available at www.sciencedirect.com journal homepage: www.europeanurology.com Hormone Therapy: Improving Therapy Decisions and Monitoring Alexandre R. Zlotta
More informationClinical Policy: Goserelin Acetate (Zoladex) Reference Number: ERX.SPA.145 Effective Date:
Clinical Policy: (Zoladex) Reference Number: ERX.SPA.145 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationLuteinising hormone-releasing hormone (LHRH) agonists in prostate cancer
B88 April 2015 2.1 Community Interest Company Luteinising hormone-releasing hormone (LHRH) agonists in prostate cancer This bulletin focuses on luteinising hormone-releasing hormone (LHRH) agonists. Currently
More informationManipulating Hormones: Androgen Suppression in Prostate Cancer Patients
Focus on CME at the University of Queen s ManitobaUniversity Manipulating Hormones: Androgen Suppression in ostate Cancer Patients By D. Robert Siemens, MD, FRCSC Case A 62-year old man presents with complaints
More informationOpen clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED
More informationProstate Cancer Case Study 2. Medical Student Case-Based Learning
Prostate Cancer Case Study 2 Medical Student Case-Based Learning The Case of Mr. Powers Prostate Cancer Recurrence Mr. Powers is a young appearing, healthy 73-year old male who underwent a radical prostatectomy
More informationand Sayo Suda Takeshi Kashiwabara *
Kashiwabara and Suda BMC Cancer (2018) 18:619 https://doi.org/10.1186/s12885-018-4541-0 RESEARCH ARTICLE Open Access Usefulness of combined androgen blockade therapy with gonadotropinreleasing hormone
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationPCa Commentary. Volume 79 May June 2014
1221 Madison Street, 1 st Floor Seattle, WA 98104 P 206-215-2480 www.seattleprostate.com PCa Commentary Volume 79 May June 2014 CONTENT: Active Surveillance Page 1 Firmagon and Lupron Page 5 ACTIVE SURVEILLANCE:
More informationTherapeutic Advances in Urology. Original Research
621471TAU0010.1177/1756287215621471Therapeutic Advances in UrologyP Iversen, J Damber research-article2015 Therapeutic Advances in Urology Original Research Degarelix monotherapy compared with luteinizing
More informationERLEADA (apalutamide) oral tablet
ERLEADA (apalutamide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationCLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE II
More informationAccuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patients
Morote et al. Journal of Biomedical Science (2017) 24:81 DOI 10.1186/s12929-017-0386-0 RESEARCH Open Access Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy
More informationNaviga2ng the Adverse Effects of ADT: Improving Pa2ent Outcomes
Naviga2ng the Adverse Effects of ADT: Improving Pa2ent Outcomes E. David Crawford, M.D. Professor of Surgery/ Urology/ Radiation Oncology University of Colorado Greetings from Colorado Disclosures Consultant:
More informationClinical Policy: Goserelin Acetate (Zoladex) Reference Number: CP.PHAR.171 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Zoladex) Reference Number: CP.PHAR.171 Effective Date: 10.01.16 Last Review Date: 11.17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of
More informationImpact of Adjuvant Androgen-Deprivation Therapy on Disease Progression in Patients with Node-Positive Prostate Cancer
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.11.741 Urological Oncology Impact of Adjuvant Androgen-Deprivation Therapy on Disease Progression in Patients with Node-Positive Prostate Cancer
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Abiraterone for the treatment of metastatic castration-resistant prostate cancer that has progressed on or after a docetaxel-based chemotherapy regimen Disease
More informationPublished on The YODA Project (
Principal Investigator First Name: David Last Name: Lorente Degree: MD Primary Affiliation: Medical Oncology Service, Hospital Provincial de Castellón E-mail: lorente.davest@gmail.com Phone number: +34
More informationTreatment of Localized Prostate Cancer With Intermittent Triple Androgen Blockade: Preliminary Results in 110 Consecutive Patients
Treatment of Localized Prostate Cancer With Intermittent Triple Androgen Blockade: Preliminary Results in 110 Consecutive Patients ROBERT L. LEIBOWITZ, STEVEN J. TUCKER Compassionate Oncology Medical Group,
More informationOpen clinical uro-oncology trials in Canada
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES
More informationJAMA. 2005;294:
CLINICAL REVIEW CLINICIAN S CORNER Androgen Deprivation Therapy for Prostate Cancer Nima Sharifi, MD James L. Gulley, MD, PhD William L. Dahut, MD ANDROGEN DEPRIVATION therapy (ADT; herein defined as medical
More informationAdjuvant Docetaxel and Abbreviated Androgen Deprivation Therapy in Patients with High Risk Prostate Cancer
The Open Prostate Cancer Journal, 21, 3, 9914 99 Open Access Adjuvant Docetaxel and Abbreviated Androgen Deprivation Therapy in Patients with High Risk Prostate Cancer Jose G. Bazan, Christopher R. King,
More informationThe Current State of Hormonal Therapy for Prostate Cancer
The Current State of Hormonal Therapy for Prostate Cancer The Current State of Hormonal Therapy for Prostate Cancer Beth A. Hellerstedt, MD; Kenneth J. Pienta, MD Dr. Hellerstedt is Fellow, Division of
More informationCost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy
available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/jval Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy S. Iannazzo, EngD,
More informationPCa Commentary. " Clinical Update New Information on Topics Presented in Earlier. Volume 78 November December 2012 CLINICAL UPDATE: ALPHARADIN
1101 Madison Street Suite 1101 Seattle, WA 98104 P 206-215-2480 www.seattleprostate.com PCa Commentary Volume 78 November December 2012 Content Page Alpharadin 1 Degarelix 2 MDV3100 4 MRI 4 Aspirin 6 "
More informationGU Guidelines Update Meeting: M0 Castrate Resistant Prostate Cancer. Dr. Simon Yu Nov 18, 2017
GU Guidelines Update Meeting: M0 Castrate Resistant Prostate Cancer Dr. Simon Yu Nov 18, 2017 Faculty/Presenter Disclosure Faculty: Dr. Simon Yu Relationships with commercial interests: Grants/Research
More informationClinical Management Guideline for Planning and Treatment. The process to be followed when a course of chemotherapy is required to treat:
Clinical Management Guideline for Planning and Treatment The process to be followed when a course of chemotherapy is required to treat: PROSTATE CANCER Patient information given at each stage following
More informationReview of Polish and international guidelines on hormonal therapy in localized prostate cancer
Review article NOWOTWORY Journal of Oncology 2016, volume 66, number 5, 403 407 DOI: 10.5603/NJO.2016.0071 Polskie Towarzystwo Onkologiczne ISSN 0029 540X www.nowotwory.edu.pl Review of Polish and international
More informationImpact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis
Original Article Yonsei Med J 218 Jul;59(5):58-587 pissn: 513-5796 eissn: 1976-2437 Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity
More informationChallenging Cases. With Q&A Panel
Challenging Cases With Q&A Panel Case Studies Index Patient #1 Jeffrey Wieder, MD Case # 1 72 year old healthy male with mild HTN Early 2011: Preop bone scan and pelvic CT = no mets Radical prostatectomy
More informationSubject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOO Subject Index Androgen antiandrogen therapy, see Hormone ablation therapy, synthesis and metabolism 49 Bacillus Calmette-Guérin adjunct therapy with transurethral resection
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD, Mary J. Mackenzie, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES CISPLATIN-BASED
More informationeuropean urology 50 (2006)
european urology 50 (2006) 483 489 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Duration of Testosterone Suppression after a 9.45 mg Implant of the GnRH-Analogue
More informationAdvanced Prostate Cancer. November Jose W. Avitia, M.D
Advanced Prostate Cancer November 4 2017 Jose W. Avitia, M.D In 2017 161,000 new cases of prostate cancer diagnosed in US, mostly with elevated PSA 5-10% will present with metastatic disease In 2017: 26,000
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationMdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often
More informationRadiation with oral hormonal manipulation for non-metastatic, intermediate or high risk prostate cancer in men 70 and older or with comorbidities
Radiation with oral hormonal manipulation for non-metastatic, intermediate or high risk prostate cancer in men 70 and older or with comorbidities Prostate cancer is predominately a disease of older men,
More informationProstate-specific antigen half-life: a new predictor of progressionfree survival and overall survival in Chinese prostate cancer patients
Original Article Asian Journal of Andrology (2009) 11: 443 450 2009 AJA, SIMM & SJTU All rights reserved 1008-682X/09 $ 32.00 www.nature.com/aja npg 443 : a new predictor of progressionfree survival and
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationFinal Appraisal Report. Ferring Pharmaceuticals Ltd. Advice No: 2109 December Recommendation of AWMSG
Final Appraisal Report Degarelix (Firmagon ) for the treatment of advanced hormone-dependent prostate cancer Ferring Pharmaceuticals Ltd Advice No: 2109 December 2009 Recommendation of AWMSG Degarelix
More informationComplete Androgen Blockade Safely Allows for Delay of Cytotoxic Chemotherapy in Castration Refractory Prostate Cancer
Clinical Urology Benefit of Androgen Blockade in Prostate Cancer International Braz J Urol Vol. 36 (3): 300-307, May - June, 2010 doi: 10.1590/S1677-55382010000300006 Complete Androgen Blockade Safely
More informationDelaying/Reducing the Risk of Clinical Tumour Progression after Primary Curative Procedures
Eur Urol 2001;40(suppl 2):17 23 Delaying/Reducing the Risk of Clinical Tumour Progression after Primary Curative Procedures M. Wirth Department of Urology, Technical University of Dresden, Germany Key
More informationMedical Treatments for Prostate Cancer
Medical Treatments for Prostate Cancer Ian F Tannock MD, PhD Daniel E Bergsagel Professor of Medical Oncology, Princess Margaret Hospital and University of Toronto March 17, 2005 Brampton 1 A hypothetical
More informationThe Natural History of Noncastrate Metastatic Prostate Cancer after Radical Prostatectomy
european urology 51 (2007) 940 948 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer The Natural History of Noncastrate Metastatic Prostate Cancer after Radical
More informationThe Return of My Cancer -Emerging Effective Therapies Jianqing Lin, MD
Februray, 2013 The Return of My Cancer -Emerging Effective Therapies Jianqing Lin, MD Why/How my cancer is back after surgery and/or radiation? Undetected micro-metastatic disease (spreading) before local
More informationProstate Cancer 2009 MDV Anti-Angiogenesis. Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy. Docetaxel/Epothilone
Prostate Cancer 2009 Anti-Angiogenesis MDV 3100 Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy Docetaxel/Epothilone Abiraterone DC therapy Bisphosphonates Denosumab Secondary Hormonal
More informationMETASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 /
METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / 2 0 1 8 Prostate Cancer- Statistics Most common cancer in men after a skin
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS
More informationFDA Approved Indication(s) Firmagon is indicated for treatment of advanced prostate cancer.
Clinical Policy: (Firmagon) Reference Number: CP.PHAR.170 Effective Date: 10.01.16 Last Review Date: 11.17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationADT vs chemo + ADT as initial treatment for advanced prostate cancer
ADT vs chemo + ADT as initial treatment for advanced prostate cancer By Hussein Khaled Prof. Medical Oncology Cairo University Possible Levels of Prostate Cancer At Diagnosis Local-Regional Disease Spread
More informationMATERIALS AND METHODS
Primary Triple Androgen Blockade (TAB) followed by Finasteride Maintenance (FM) for clinically localized prostate cancer (CL-PC): Long term follow-up and quality of life (QOL) SJ Tucker, JN Roundy, RL
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationEORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924
EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924 Title of the Study Medical Condition Androgen deprivation therapy and high dose radiotherapy with or without
More informationComparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients
Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients R Kuefer 1, BG Volkmer 1, M Loeffler 1, RL Shen 2, L Kempf 3, AS Merseburger 4, JE Gschwend
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES CISPLATIN-BASED
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationSix-Month Depot Formulation of an LHRH agonist for the Treatment of Advanced Prostate Cancer Efficacy and Tolerability
Original article 2015 Journal of Medical Drug Reviews. All rights reserved. J Med Drug Rev 2015;5:33 38 Six-Month Depot Formulation of an LHRH agonist for the Treatment of Advanced Prostate Cancer Efficacy
More informationNCCN Guidelines for Prostate Cancer V Web teleconference 06/17/16 and 06/30/17
Guideline Page and Request PROS-1 Submission from Myriad Genetic Laboratories, Inc. Request addition of recommendation for genetic risk assessment/testing to the Initial Clinical Assessment algorithm for
More informationWHICH PATIENTS WITH PROSTATE CANCER ARE ACTUALLY CANDIDATES FOR HORMONE THERAPY?
Clinical Urology International Braz J Urol Official Journal of the Brazilian Society of Urology HORMONE THERAPY IN PROSTATE CANCER Vol. 30 (6): 455-465, November - December, 2004 WHICH PATIENTS WITH PROSTATE
More informationTreatment of Advanced Prostate Cancer
Treatment of Advanced Prostate Cancer Wm. Kevin Kelly, DO Associate Professor of Medicine and Surgery Yale University Yale University School of Medicine Advanced Prostate Cancer Metastatic Cancer Prostate
More informationSession 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy
Session 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy October- 2015 ESMO 2004 October- 2015 Fyraftensmøde 2 2010 October- 2015 Fyraftensmøde 3 SWOG 9916 OS
More informationFrancesco Bertoldo. Metabolic Bone Diseases and Osteoncology Unit DRUG INDUCED S OSTEOPOROSIS: ANDROGEN DEPRIVATION THERAPY
DRUG INDUCED S OSTEOPOROSIS: ANDROGEN DEPRIVATION THERAPY Francesco Bertoldo Metabolic Bone Diseases and Osteoncology Unit Department of Medicine University di Verona EPIDEMIOLGY OF PROSTATE CANCER Prostate
More informationRisk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy
RESEARCH ARTICLE Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy Satoru Taguchi, Hiroshi Fukuhara*, Shigenori Kakutani,
More informationProstate Cancer. Dr. Andres Wiernik 2017
Prostate Cancer Dr. Andres Wiernik 2017 Objectives YES!!! 1. Epidemiology 2. Biology or Natural History of Prostate Cancer 3. Treatment NO!!! 1. Prostate Cancer Screening - controversies Which is the most
More informationDivision of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine, Durham, NC
LHRH AGONISTS: CONTEMPORARY ISSUES The Evolving Definition of Advanced Prostate Cancer Judd W. Moul, MD, FACS Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine,
More informationLong-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with Radical Prostatectomy
Jpn J Clin Oncol 2012;42(6)541 547 doi:10.1093/jjco/hys043 Advance Access Publication 28 March 2012 Long-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with
More informationMOLECULAR AND CLINICAL ONCOLOGY 4: , 2016
MOLECULAR AND CLINICAL ONCOLOGY 4: 839-844, 2016 Clinical outcomes of anti androgen withdrawal and subsequent alternative anti-androgen therapy for advanced prostate cancer following failure of initial
More informationreviews LHRH Agonists in the Treatment of Advanced Carcinoma of the Prostate therapy
reviews therapy LHRH Agonists in the Treatment of Advanced Carcinoma of the Prostate Martin I. Resnick, MD, Lester Persky Professor and Chief, Department of Urology, Case Western Reserve University School
More information